>
Switch to:

Myovant Sciences Gross Profit

: $179.4 Mil (TTM As of Mar. 2022)
View and export this data going back to 2016. Start your Free Trial

Myovant Sciences's gross profit for the three months ended in Mar. 2022 was $39.8 Mil. Myovant Sciences's gross profit for the trailing twelve months (TTM) ended in Mar. 2022 was $179.4 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Myovant Sciences's gross profit for the three months ended in Mar. 2022 was $39.8 Mil. Myovant Sciences's Revenue for the three months ended in Mar. 2022 was $57.6 Mil. Therefore, Myovant Sciences's Gross Margin % for the quarter that ended in Mar. 2022 was 69.18%.

Myovant Sciences had a gross margin of 69.18% for the quarter that ended in Mar. 2022 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of Myovant Sciences was 96.69%. The lowest was 77.68%. And the median was 87.19%.


Myovant Sciences Gross Profit Historical Data

The historical data trend for Myovant Sciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Gross Profit
Premium Member Only Premium Member Only - - - 57.35 179.42

Myovant Sciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Gross Profit Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.64 34.77 66.72 38.11 39.83

Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Gross Profit Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Gross Profit falls into.



Myovant Sciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Myovant Sciences's Gross Profit for the fiscal year that ended in Mar. 2022 is calculated as

Gross Profit (A: Mar. 2022 )=Revenue - Cost of Goods Sold
=230.972 - 51.551
=179.4

Myovant Sciences's Gross Profit for the quarter that ended in Mar. 2022 is calculated as

Gross Profit (Q: Mar. 2022 )=Revenue - Cost of Goods Sold
=57.567 - 17.742
=39.8

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $179.4 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Myovant Sciences's Gross Margin % for the quarter that ended in Mar. 2022 is calculated as

Gross Margin % (Q: Mar. 2022 )=Gross Profit (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=39.8 / 57.567
=69.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Myovant Sciences  (NYSE:MYOV) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Myovant Sciences had a gross margin of 69.18% for the quarter that ended in Mar. 2022 => Durable competitive advantage


Myovant Sciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo officer: Chief Medical Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie director C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen director C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Seely Lynn director, officer: Principal Executive Officer 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)